Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. (4th March 2018)

• Record Type: Journal Article
• Authors: Deitelzweig, S.; Farmer, C.; Luo, X.; Li, X.; Vo, L.; Mardekian, J.; Fahrbach, K.; Ashaye, A.
• Is Part Of: Current medical research and opinion. Volume 34:Number 3(2018)
• Page Start: 487
• Page End: 498
• Publication Date: 2018-03-04
• Subjects: Direct oral anticoagulants (DOACs) -- Novel oral anticoagulants (NOACs) -- Warfarin -- Non-valvular atrial fibrillation (NVAF) -- major bleeding -- Network meta-analysis (NMA) -- systematic review; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2017.1411793
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objective: To conduct a systematic literature review (SLR) and network meta-analysis (NMA) of real-world studies comparing major bleeding risk among patients with non-valvular atrial fibrillation (NVAF) on direct oral anticoagulants (DOACs) or warfarin. Methods: Systematic searches were conducted in MEDLINE and Embase for full-text articles published between January 1, 2003 and March 18, 2017. Eligible studies compared at least two of the following in a real-world setting: warfarin, apixaban, dabigatran, rivaroxaban, or edoxaban. A Bayesian NMA was conducted to estimate hazard ratios (HRs) for major bleeding using a random-effects model. Results: Eleven studies were included in the NMA. Nine studies included DOACs vs Warfarin comparisons, and four studies included DOACs vs DOACs comparisons (two studies included both comparisons). Median follow-up duration ranged from 2.6–31.2 months. No evidence was identified for edoxaban. Apixaban was associated with a significantly lower risk of major bleeding compared to other oral anticoagulants (warfarin HR = 0.58; 95% credible interval [CrI] = 0.48–0.69; dabigatran = 0.73; 0.61–0.87; rivaroxaban = 0.55; 0.46–0.66). Dabigatran was associated with a significantly lower risk than warfarin (0.79; 0.71–0.88) and rivaroxaban (0.76; 0.67–0.85), and rivaroxaban was not statistically different from warfarin (1.05; 0.91–1.19). Sensitivity analyses with standard dose and sponsorship showed consistent results. Conclusion: DOACs were associated with lower or similar risk of major bleeding compared with warfarin in NVAF patients. Apixaban was associated with a significantly lower risk of major bleeding than other DOACs. Dabigatran was associated with a significantly lower risk of major bleeding compared to rivaroxaban and warfarin.